Related Experiment Video
Updated: Jan 6, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.6K
Circulating Pin1 Levels in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Case-Control Study
Lynn Willems1, Eleonora Camilleri2, Elise Bosmans1
1Laboratory of Respiratory Diseases & Thoracic Surgery (BREATHE), Department of Chronic Diseases & Metabolism (CHROMETA) KU Leuven - University of Leuven Leuven Belgium.
Pulmonary Circulation
|November 20, 2025
Summary
Circulating Pin1 levels do not generally distinguish chronic thromboembolic pulmonary hypertension (CTEPH) from controls. However, Pin1 may play a sex-specific role in CTEPH development and severity, particularly in men.
Area of Science:
- Cardiovascular Research
- Biochemistry
- Pulmonary Medicine
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe complication of pulmonary embolism (PE) with unclear mechanisms.
- Peptidyl-prolyl cis/trans isomerase (Pin1) is implicated in thrombosis, inflammation, and vascular remodeling, suggesting a potential role in CTEPH.
Purpose of the Study:
- To investigate the association between circulating Pin1 levels and the risk and severity of CTEPH.
- To explore potential sex-specific differences in this association.
Main Methods:
- A case-control study involving 329 CTEPH patients, 350 post-acute PE patients, and 350 healthy individuals.
- Circulating Pin1 levels measured by ELISA; associations analyzed using multivariable regression, stratified by sex.
Main Results:
- Overall Pin1 levels did not differ significantly between CTEPH patients and controls.
- Male CTEPH patients exhibited higher Pin1 levels than controls, while female CTEPH patients showed lower levels.
- In men, elevated Pin1 correlated with improved hemodynamics, exercise capacity, and lower NT-proBNP.
Conclusions:
- Circulating Pin1 is not a standalone biomarker for CTEPH diagnosis.
- Results suggest a sex-specific association of Pin1 with CTEPH, potentially reflecting underlying pathological mechanisms.
- Further research is warranted to explore Pin1's utility in multimodal CTEPH risk stratification strategies.
More Related Videos
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
267
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
267
01:30Pulmonary Hypertension: Classification and Pathogenesis
533
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
533
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
411
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
411
01:29Pulmonary Embolism I: Introduction
457
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
457
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:30Venous Thrombosis I: Introduction
245
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
245